Видео ютуба по тегу Idh2

AML: Significance of the IDH2 Mutation
AML: Significance of the IDH2 Mutation
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?
How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?
Enasidenib for IDH2-mutated MDS
Enasidenib for IDH2-mutated MDS
Treatment Options for Relapsed or Refractory AML: IDH1, IDH2, and FLT3 - Blood Cancer OncTalk
Treatment Options for Relapsed or Refractory AML: IDH1, IDH2, and FLT3 - Blood Cancer OncTalk
Case Review: IDH2-Mutated Acute Myeloid Leukemia
Case Review: IDH2-Mutated Acute Myeloid Leukemia
IDH Mutations in Cancer
IDH Mutations in Cancer
Managing Treatment for IDH2-Mutated AML
Managing Treatment for IDH2-Mutated AML
Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY
Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY
Case 3: IDH2-Mutated AML
Case 3: IDH2-Mutated AML
Phase II trial of enasidenib in IDH2-mutant MDS
Phase II trial of enasidenib in IDH2-mutant MDS
David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia
David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia
IDH2 Mutation Allows Myelod Differentiation #aml | Jane Liesveld | ASH 2023
IDH2 Mutation Allows Myelod Differentiation #aml | Jane Liesveld | ASH 2023
The impact of IDH mutated clones in NPM1+ AML
The impact of IDH mutated clones in NPM1+ AML
The next steps for the IDH2 inhibitor drug enasidenib
The next steps for the IDH2 inhibitor drug enasidenib
Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia
Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
Advantages of Oral Enasidenib in IDH2-Mutated AML
Advantages of Oral Enasidenib in IDH2-Mutated AML
AML On The Go: Targeted Therapy of IDH1/IDH2 Mutated AML
AML On The Go: Targeted Therapy of IDH1/IDH2 Mutated AML